| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q3 2021 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LIQUIDIA CORPORATION | 7 | Q2 2024 | 49.0% |
| ALIMERA SCIENCES INC | 7 | Q2 2024 | 24.5% |
| ANIKA THERAPEUTICS INC | 7 | Q2 2024 | 14.6% |
| EVOLUS INC | 7 | Q2 2024 | 10.9% |
| VERONA PHARMA PLC | 7 | Q2 2024 | 6.2% |
| AGIOS PHARMACEUTICALS INC | 7 | Q2 2024 | 5.2% |
| EXELIXIS INC | 6 | Q2 2024 | 11.5% |
| STANDARD BIOTOOLS INC | 5 | Q4 2023 | 11.7% |
| ADMA BIOLOGICS INC | 5 | Q4 2023 | 8.6% |
| SOCIETAL CDMO INC | 5 | Q4 2023 | 2.0% |
View Caligan Partners LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Anika Therapeutics, Inc. | May 30, 2024 | 1,435,993 | 9.7% |
| STANDARD BIOTOOLS INC. | January 08, 2024 | 7,042,413 | 2.4% |
| EXELIXIS, INC. | June 02, 2023 | 910,730 | 0.3% |
| ADMA BIOLOGICS, INC. | December 09, 2022 | 10,264,311 | 4.6% |
| AMAG PHARMACEUTICALS, INC. | November 16, 2020 | ? | ? |
| Knowles Corp | September 30, 2019 | 102,674 | 0.0% |
View Caligan Partners LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-09-18 |
| SC 13D/A | 2024-09-18 |
| 4 | 2024-09-12 |
| SC 13D/A | 2024-09-12 |
| 4 | 2024-09-04 |
| SC 13D/A | 2024-09-04 |
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| 4 | 2024-06-24 |
| SC 13D/A | 2024-06-24 |
View Caligan Partners LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.